Featured Research

from universities, journals, and other organizations

In vitro tests show that clinically tested drug overcomes resistance to potential new cancer therapy

Date:
April 3, 2014
Source:
University Saarland
Summary:
Results from laboratory experiments carried out by a team of molecular biologists have identified a strategy for overcoming resistance to a new therapeutic opportunity for prostate cancer patients and for potentially suppressing the migration of cancer cells. The new therapeutic approach, which is currently being studied by numerous research groups, aims to destroy cancer cells by influencing cellular calcium distribution.

Results from laboratory experiments carried out by a team of molecular biologists at Saarland University have identified a strategy for overcoming resistance to a new therapeutic opportunity for prostate cancer patients and for potentially suppressing the migration of cancer cells. The new therapeutic approach, which is currently being studied by numerous research groups, aims to destroy cancer cells by influencing cellular calcium distribution.

However, the research team, supervised by Professor Richard Zimmermann and Dr Markus Greiner, found that in about half of the patients examined, a cellular mechanism was present that could impede the efficacy of the new therapy. The molecular biologists discovered that this resistance was caused by an increased concentration of the protein Sec62 in the tumor cells. Results from their laboratory cell line experiments indicate that a pharmaceutically active agent previously used in the treatment of psychotic disorders can counteract the observed cellular resistance as well as supress cell migration. The research team has published its findings in the medical journal BMC Cancer.

Prostate cancer is the most common malignant tumor in men. A new therapeutic approach to combating the disease is currently the subject of international research. In recent years, US scientists have developed a number of analogues of thapsigargin that are capable of selectively killing tumor cells by emptying the calcium stores in these cells. But recent research by scientists at Saarland University's Faculty of Medicine in Homburg has demonstrated that in approximately half of the patients suffering from prostate cancer, the tumor cells can be expected to show a resistance to this new form of therapy. 'The resistance mechanism is due to a higher concentration of the protein Sec62,' explains Professor Richard Zimmermann. As a result of increased Sec62 levels the protein calmodulin can close the calcium leak channels more efficiently in the membrane of the important intracellular calcium store known as the endoplasmic reticulum. 'This is why tumor cells with a higher concentration of Sec62 show greater resistance to treatment regimens based on thapsigargin analogues,' says Zimmermann.

Working with tumor cell cultures in the laboratory, Zimmermann's group at the Department of Medical Biochemistry and Molecular Biology has found a possible solution to the problem and their results have been published in the journal BMC Cancer. 'Using tumor cell lines, we were able to show that a substance called trifluoperazine (TFP) was able to counteract the observed resistance. TFP has been used as an antipsychotic and was marketed in Germany under the brand Jatroneutral® where it was used in the treatment of psychotic disorders,' explains Dr Markus Greiner, a member of Professor Zimmermann's research team. 'TFP binds directly to the protein calmodulin and thus impairs the calmodulin-mediated closure of the calcium channels,' explains Greiner.

Sec62 has been shown to be an important tumor marker, i.e. a protein that occurs at enhanced concentrations in tumor cells, not only in prostate carcinomas, but also in thyroid and lung carcinomas. The Homburg researchers see a correlation between the presence of Sec62 protein and a more aggressive tumor and hence lower patient survival rates. The research team also measured increased Sec62 concentrations in tumors that had already metastasized. 'Calcium is an important signalling molecule that regulates cell migration, which is itself an important contributor to tumor metastasis,' says Markus Greiner. The calcium in the cells ensures that the cells can detect the direction in which they are migrating. If these tumor cells are treated with TFP, the calcium store will be emptied and the cells essentially lose their orientation. 'This leads to an almost complete cessation of cellular migration,' explains Greiner.

'We propose a therapeutic approach based on TFP in combination with thapsigargin analogues. In future, this may be a therapeutic option for those many patients whose tumors have a high cellular concentration of Sec62, which might make them unsuitable for treatment with thapsigargin,' says Greiner. The results obtained by the Homburg research team will now be evaluated in tumor model studies before any clinical trials can be proposed.


Story Source:

The above story is based on materials provided by University Saarland. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maximilian Linxweiler, Stefan Schorr, Nico Schäuble, Martin Jung, Johannes Linxweiler, Frank Langer, Hans-Joachim Schäfers, Adolfo Cavalié, Richard Zimmermann, Markus Greiner. Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer, 2013; 13 (1): 574 DOI: 10.1186/1471-2407-13-574

Cite This Page:

University Saarland. "In vitro tests show that clinically tested drug overcomes resistance to potential new cancer therapy." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403084404.htm>.
University Saarland. (2014, April 3). In vitro tests show that clinically tested drug overcomes resistance to potential new cancer therapy. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2014/04/140403084404.htm
University Saarland. "In vitro tests show that clinically tested drug overcomes resistance to potential new cancer therapy." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403084404.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) — Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) — Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) — Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) — The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins